男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Application given for gene therapy trials to treat blood disease

By Liu Zhihua | chinadaily.com.cn | Updated: 2021-01-19 14:44
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

Chinese biotech company EdiGene Inc announced on Monday the Center for Drug Evaluation of the China National Medical Products Administration has approved the company's Investigational New Drug application for ET-01, a CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, a blood disease characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload.

That marks the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approval in China.

The Beijing-based company develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases. Previously, the company announced the acceptance of the IND by CDE on Oct 27, 2020.

Wei Dong, CEO of EdiGene, said the company will roll out phase I clinical trials soon.

"We are embarking on a new journey as a clinical-stage company. We will continue to translate cutting-edge gene-editing technology and advance our pipeline, with a goal of providing better choices for patients in China and around the world," he said.

ET-01 is an investigational, autologous, ex vivo gene-editing therapy. The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess safety and efficacy in transfusion dependent β-thalassemia patients.

In China, it is estimated there are over 300,000 patients with thalassemia major or thalassemia intermediate. Serious unmet medical needs remain for transfusion dependent β-thalassemia patients today.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 麻城市| 亳州市| 绍兴市| 九龙县| 无极县| 秦安县| 清原| 南投县| 沁水县| 盘山县| 同心县| 庆云县| 英山县| 象山县| 东城区| 喜德县| 文登市| 固原市| 高邮市| 九龙城区| 微博| 班玛县| 吉木乃县| 汝阳县| 定襄县| 韩城市| 永靖县| 浦城县| 卓资县| 郸城县| 东莞市| 凭祥市| 尉犁县| 科技| 泸水县| 甘肃省| 肇州县| 建宁县| 宝应县| 汽车| 甘德县|